(Total Views: 640)
Posted On: 07/01/2024 5:02:26 PM
Post# of 148863
I just reviewed Dr Noureddin’s NASH slides from the investors presentation December 2022. This data really needs to be published! Do we have any hints on a timeline for the Leronlimab phase 2a study involving NASH publication? Provocative is an understatement. Publication in concert with the MASH study involving mice with results in the Fall of this year would be very powerful.
Noting here also that study hit a statistically significant p value for ENRAGE with the 350 mg dose. I believe that to be one of the secondary endpoints in the HIV inflammation study.
Leronlimab can carry a tune, pitch perfect and pure tone when it comes to diseases with inflammation as an underpinning.
Noting here also that study hit a statistically significant p value for ENRAGE with the 350 mg dose. I believe that to be one of the secondary endpoints in the HIV inflammation study.
Leronlimab can carry a tune, pitch perfect and pure tone when it comes to diseases with inflammation as an underpinning.
(13)
(0)Scroll down for more posts ▼
